Making the difference
Khondrion was founded by Prof. Dr. Jan Smeitink, a world-leader in mitochondrial medicine. He has devoted his entire career to the care of mitochondrial disease patients, to better understand the complexity of this disease and his life mission is to develop a treatment for these high impacts, often early fatal group of disorders. Fully operational since 2012 and located in Nijmegen, The Netherlands, Khondrion primarily focuses on the development of innovative therapies for inherited mitochondrial diseases, including Leigh Disease, MELAS, Leber’s Hereditary Optic Neuropathy and other Respiratory Chain / Oxidative Phosphorylation disorders.
Our company's focus is on our own product development programmes. We have extensive experience in mitochondrial medicine, unique quantitative live-cell imaging technologies and in-depth characterised patients-derived cell panels. In this scope, we have developed a portfolio of pre-clinical drug candidates, among them the frontrunner KH176 is currently under clinical evaluation.
Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol
Khondrion announces publication in Scientific Reports
Khondrion joins Consortium researching metabolomic processes to predict and prevent COVID-19
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA
Sonlicromanol mogelijk ook ontstekingsremmer bij COVID-19
Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19
Khondrion announces 1st patients dosed in Phase IIb study of Sonlicromanol for mitochondrial disease
Khondrion granted Orphan Drug Designation for KH176
Nijmeegse Khondrion haalt Europese subsidie binnen voor uniek medicijn
9 miljoen voor 5 Nederlandse innovatieve scale-ups
Khondrion will present first results of KHENERGY study
Is dit bedrijf voor jou een potentiële match? Neem dan contact op met:
Mirjam van den Bosch
Naar onze partners
Health Valley Netherlands gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over cookies.